Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Int J Gynecol Cancer. 2010 Jul;20(5):704-16
Authors: Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M
The presence of a germline BRCA mutation defines a genotype-specific group of women whose invasive ovarian cancer is associated with an increasingly well-defined prognostic and chemosensitivity biological profile. To determine the criteria that may be used to select patients for BRCA treatment-focused genetic testing, we performed a systemic literature search of studies that assessed BRCA1 and BRCA2 mutation frequency in women with ovarian cancer unselected for family history. The results are discussed with regard to the added clinical value gained by identifying a germline BRCA mutation at the time of the ovarian cancer diagnosis.
PMID: 20973257 [PubMed - indexed for MEDLINE]
